Satralizumab-mwge is a biosimilar to Satralizumab
- TRADE NAME: Enspryng (Genentech)
- INDICATIONS: Treatment of neuromyelitis optica spectrum disorder.
- CLASS: Interleukin-6 (IL-6) antagonist, Monoclonal antibody
- HALF-LIFE: 22–37 days
- FDA APPROVAL DATE: 08/14/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No adequate data on the developmental risk associated with use in pregnant women.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 05/23/2024
